Lenacapavir's 6-Month HIV PrEP Shows Promise, Rollout Gets Mixed Reviews

For health systems and HIV prevention programs, lenacapavir is a potential paradigm shift: a twice-yearly injectable that bypasses daily pill adherence and has shown unprecedented protection in the PURPOSE 1 and 2 trials. But a new NPR report from Kalisizo, Uganda — where 13% of residents are living with HIV — highlights that clinical efficacy alone won't guarantee population-level impact. The gap between trial-site success and real-world delivery is where the rollout is getting mixed reviews.

The emergence of lenacapavir as a twice-yearly injectable HIV prevention tool represents one of the most significant developments in the PrEP landscape in years. Reporting from Kalisizo, Uganda, a district along Lake Victoria where 13% of residents are living with HIV, captures both the promise and the messy reality of rollout. The drug is currently approved only for HIV-negative individuals as pre-exposure prophylaxis, or PrEP. Unlike daily oral PrEP, lenacapavir is injected into the abdomen and releases slowly over six months, meaning patients need only two clinic visits per year. For a 22-year-old trial participant named Irene, who has been in one of the influential lenacapavir trials for three years and is due to give birth in three weeks, the drug has effectively removed HIV from her list of fears. She asked NPR to use only her first name because participating in an HIV trial can lead neighbors to assume she is living with HIV. Her experience illustrates why the rollout is drawing mixed reviews: even a highly effective product has to navigate stigma, clinic access, and real-world health system constraints.

“

But a new NPR report from Kalisizo, Uganda — where 13% of residents are living with HIV — highlights that clinical efficacy alone won't guarantee population-level impact.

The clinical backbone of this story is the PURPOSE 1 and PURPOSE 2 trial program. About two years before the August 2026 report, these trials delivered what sources describe as unprecedented results. An independent monitoring committee concluded lenacapavir was so effective that the randomized phase was halted early. While the visible excerpts do not provide the exact incidence reduction figures, the fact that an independent body stopped randomization early is itself a strong signal of efficacy. The mechanism addresses two persistent barriers in HIV prevention: adherence and efficacy. Daily pills often fail because patients struggle to take them consistently, and even highly motivated users can miss doses. Lenacapavir removes the daily decision entirely, replacing it with a twice-yearly healthcare encounter. An oral version exists but requires more frequent dosing, which undercuts the adherence advantage.

The mixed reviews around rollout reflect the gap between trial-site performance and population-level delivery. In the clinical trial setting, participants receive injections at dedicated sites with structured follow-up. Scaling that model to rural health posts, district hospitals, and community clinics requires trained staff, reliable supply chains, and enough patient trust to overcome stigma. Irene's decision to use only her first name underscores how deeply HIV-related discrimination remains embedded in the communities that most need prevention. Even with a six-month injection, a patient must still travel to a facility and be seen receiving care. In an environment where participation in an HIV trial can be misread as an HIV diagnosis, that visibility can deter uptake. The rollout's mixed reviews therefore are not primarily about whether lenacapavir works — the trial data settled that question — but about whether health systems can deliver it equitably and without reinforcing stigma.